Provention Bio (PRVB) Stock Price, News & Analysis

Company Overview

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Key Stats

• Today's Range: $24.98 to $24.98
• 50-Day Range: $23.74 to $24.98
• 52-Week Range: $3.18 to $25.00
• Volume: 218,200 shs
• Average Volume: 2.28 million shs
• Market Capitalization: $2.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRVB Stock Analysis - Frequently Asked Questions

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PRVB
• CUSIP: N/A
• CIK: 1695357
• Web: www.proventionbio.com
• Phone: (908) 428-9136
• Fax: N/A
• Employees: 82
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-113,570,000.00
• Net Margins: -880.69%
• Pretax Margin: -984.54%
• Return on Equity: -103.36%
• Return on Assets: -69.08%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 1.93
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $12.90 million
• Price / Sales: 183.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.40 per share
• Price / Book: 17.84

Miscellaneous

• Outstanding Shares: 94,780,000
• Free Float: 82,365,000
• Market Cap: $2.37 billion
• Optionable: Not Optionable
• Beta: 2.47